Systemic sclerosis & Raynaud's
Assessment of markers of primary aldosteronism in systemic sclerosis and their relationships with renal and cardiovascular outcomes
Authors' conclusion
HTN was common in this SSc cohort, and prevalence of positive PA screening test was estimated at 12% among hypertensive SSc patients
Study context
- Population
- Adult systemic sclerosis (SSc) patients and normotensive healthy controls, single centre
- Participants
- 112 vs 48
- Exposure
- SSc patients vs normotensive healthy controls (HC)
- SScn = 112
- HCn = 48reference
- Outcome
- Prevalence and management of HTN, prevalence of positive PA screening (ARR), and associations of PA markers with HTN and SSc-related outcomes
Methodological detailssingle-centre, multivariable regression modelling
- Single-centre
- Multivariable regression modelling
Main finding
As reported in the abstract
Positive baseline ARR (PA screening) in SSc
SSc
8%
9 of 112
- Positive baseline aldosterone:renin ratio (ARR) in hypertensive SSc subset
- 12% (5/41)
Observational data: associations, not effects.
Further findings
- Hypertension (HTN) prevalence in SSc · baseline and last follow-up (median 5.1 years)
- 37% · 41 of 112
- HTN prevalence in SSc — HTN at last follow-up visit
- 52%
- HTN prevalence in SSc: median follow-up 5.1 years
Associations of primary aldosteronism (PA) biomarkers with SSc-related renal and cardiovascular outcomes or HTN at last follow-up
- No associations observed
Original publication
Assessment of markers of primary aldosteronism in systemic sclerosis and their relationships with renal and cardiovascular outcomes. RMD Open. Published 15 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →